A new study published in The American Journal of Drug and Alcohol Abuse found that 11.7% of adults entering New York City nightclubs in 2024 tested positive for THCA-A, and 8.9% tested positive for CBN—two cannabinoids not typically included in routine screenings. Conducted by researchers from Stanford University, the University of California, and NYU Grossman …
Category: News
Study Finds Marijuana Not to Blame for Brain Wave Changes in Psychosis
According to the results of a new study published in the European Archives of Psychiatry and Clinical Neuroscience, recent cannabis use does not significantly affect key brain activity patterns in individuals with psychosis. Researchers examined 93 patients diagnosed with schizophrenia or bipolar disorder, dividing them into recent cannabis users and non-users. EEG readings were compared …
Study Finds THC and CBD Do Not Affect Estrogen Production in Key Ovarian Cells
A new study published in the journal Reproductive Toxicology by researchers at the University of Ottawa found that cannabinoids such as THC and CBD do not impact estrogen production in human granulosa cells, which play a crucial role in female reproductive health. “As cannabis becomes more accessible globally, its use among women of reproductive age …
Survey Finds 48% of Adults in Australia Support Legalizing Cannabis, Up 15% Since 2015
Support for legal marijuana continues to grow in Australia, with new polling showing that nearly half of all adults now believe it should be allowed. According to survey data released by Roy Morgan, 48% of Australians now support legalizing marijuana—up 15% over the past decade, from 33% in 2015 and 42% in 2019. Opposition has …
U.S. House Appropriations Committee Approves Bill to Ban Hemp-Derived THC Products Nationwide
The U.S. House Appropriations Committee has approved a federal spending bill that includes a broad ban on hemp-derived THC products, advancing the legislation to the House floor for further consideration. The proposed ban is part of the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Bill for fiscal year 2026, which the …
Vermont Cannabis Sales Top $46 Million in First Four Months of 2025
Vermont’s legal cannabis industry brought in $46.2 million in taxable sales from January through April 2025, according to newly released data from the state’s Department of Taxes. The total represents a 5% increase over the same four-month period in 2024, when sales totaled approximately $43.9 million. April 2025 alone saw $11.78 million in taxable cannabis …
Texas Governor Greg Abbott Wants To Legalize Marijuana, Says Lieutenant Governor
Texas Lieutenant Governor Dan Patrick says Governor Greg Abbott is in favor of legalizing marijuana, following the governor’s veto of a bill that would have banned hemp-derived THC. Patrick made the comments during a Monday interview with San Antonio’s News Radio 1200 WOAI, where he blasted Abbott’s surprise veto of a bill that would have …
New Poll Finds Majority of Utah Voters Support Legalizing Recreational Marijuana
A new Deseret News/Hinckley Institute of Politics poll shows a growing shift in public opinion around marijuana policy in Utah, with a majority of registered voters now expressing support for legalizing recreational cannabis. The survey, conducted last month among 805 registered voters, found that 53% support some form of legalization for adult use—a notable increase …
70% of U.S. Voters Support Federal Cannabis Reform, New National Survey Finds
A strong majority of U.S. voters support ending federal cannabis prohibition and allowing states to set their own laws, according to a new nationwide poll conducted by Forbes Tate Partners on behalf of the Coalition for Cannabis Policy, Education, and Regulation (CPEAR). The survey of 2,051 registered voters aged 21 and older found that 70% …
Compass Pathways’ Psilocybin Drug Hits Primary Goal in Landmark Phase 3 Depression Trial
Compass Pathways says a single dose of its synthetic psilocybin significantly reduced depression symptoms in patients who haven’t responded to standard treatments, marking a key milestone in what could become the first FDA-approved psychedelic therapy for treatment-resistant depression. The company announced that its lead candidate, COMP360, met the primary endpoint in its Phase 3 COMP005 …
Sponsored
